The HPV vaccine can protect up to six different cancers. Despite being licensed for over a decade, the HPV vaccination coverage remains suboptimal due to individual-level, provider-level, and health system-related barriers. Furthermore, disparities in uptake are also evident. The CADS lab is using novel data-driven approaches to understand the underlying barriers, unravel disparities, and identify opportunities to address them.
Notable publications in this area
Low cervical cancer screening uptake and adherence among women unvaccinated against HPV
Human papillomavirus (HPV) vaccination and cervical cancer screening are cornerstone interventions for cervical cancer elimination. In this study, we showed that women never vaccinated against HPV are less likely to undergo or adhere to cervical cancer screening recommendations. Notably, 1 in 3 (an estimated 2.6 million) unvaccinated women never received cervical cancer screening compared to 1 in 6 (an estimated 1.9 million) vaccinated women.
Rising safety concerns related to HPV vaccination and concurrent decline in adverse events reporting
A rising number of parents (13% in 2015 to 23% in 2018) in the US are citing safety as their primary concern for HPV vaccine hesitancy in the USA. The proportion of parents citing safety concerns as their main reason for not initiating the HPV vaccine series increased in 30 states. Notably, over 200% rise in safety concerns was observed in California, Hawaii, South Dakota, and Mississippi. During the same duration, the adverse events reporting rate decreased.